GlucoTrack Cost Of Revenue vs Revenue Per Share Analysis

GCTK Stock

USD 0.26 0.01 4.00%

GlucoTrack financial indicator trend analysis is much more than just examining GlucoTrack latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether GlucoTrack is a good investment. Please check the relationship between GlucoTrack Cost Of Revenue and its Revenue Per Share accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlucoTrack. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.

Cost Of Revenue vs Revenue Per Share

Cost Of Revenue vs Revenue Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of GlucoTrack Cost Of Revenue account and Revenue Per Share. At this time, the significance of the direction appears to have weak relationship.

The correlation between GlucoTrack's Cost Of Revenue and Revenue Per Share is 0.32. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Revenue Per Share in the same time period over historical financial statements of GlucoTrack, assuming nothing else is changed. The correlation between historical values of GlucoTrack's Cost Of Revenue and Revenue Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of GlucoTrack are associated (or correlated) with its Revenue Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Revenue Per Share has no effect on the direction of Cost Of Revenue i.e., GlucoTrack's Cost Of Revenue and Revenue Per Share go up and down completely randomly.

Correlation Coefficient

0.32

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Cost Of Revenue

Cost of Revenue is found on GlucoTrack income statement and represents the costs associated with goods and services GlucoTrack provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.

Most indicators from GlucoTrack's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GlucoTrack current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlucoTrack. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.Selling General Administrative is expected to rise to about 2.4 M this year, although the value of Issuance Of Capital Stock will most likely fall to about 5.2 M.

	2021	2022	2023	2024 (projected)
Cost Of Revenue	42K	23K	13K	12.4K
Reconciled Depreciation	42K	23K	25K	32.9K

Cost Of Revenue Reconciled Depreciation

GlucoTrack fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Net Receivables	Inventory	Other Liab	Net Tangible Assets	Other Assets
Common Stock Shares Outstanding		0.5	-0.15	-0.25	-0.06	0.61	0.19	-0.55	-0.73	0.02	0.54	-0.12	-0.56	0.54	-0.51	-0.25	0.8	-0.48	0.51	0.47	-0.35	-0.12	-0.31	-0.75	0.84	-0.81
Total Assets	0.5		0.2	-0.28	-0.21	0.52	0.17	-0.97	-0.34	-0.23	0.98	-0.14	-0.44	0.98	-0.12	0.08	0.39	-0.15	1.0	0.31	0.07	-0.07	-0.18	-0.33	0.53	-0.44
Short Long Term Debt Total	-0.15	0.2		-0.45	-0.51	0.0	-0.06	-0.18	0.41	-0.57	0.27	0.0	0.07	0.27	0.19	-0.22	-0.37	0.09	0.2	-0.05	0.54	-0.1	-0.34	0.31	-0.27	0.25
Other Current Liab	-0.25	-0.28	-0.45		0.95	-0.48	0.28	0.34	-0.26	0.9	-0.38	0.4	0.46	-0.38	0.29	0.06	0.15	0.44	-0.3	0.24	0.02	0.54	0.46	-0.14	0.02	0.13
Total Current Liabilities	-0.06	-0.21	-0.51	0.95		-0.43	0.48	0.3	-0.35	0.98	-0.34	0.53	0.47	-0.34	0.25	0.01	0.25	0.41	-0.24	0.35	-0.03	0.61	0.55	-0.23	0.13	0.02
Total Stockholder Equity	0.61	0.52	0.0	-0.48	-0.43		-0.24	-0.66	-0.5	-0.4	0.63	-0.52	-0.78	0.63	-0.9	0.04	0.59	-0.92	0.54	0.37	-0.56	-0.56	-0.67	-0.65	0.72	-0.66
Property Plant And Equipment Net	0.19	0.17	-0.06	0.28	0.48	-0.24		0.02	0.0	0.52	0.02	0.92	0.57	0.02	0.26	-0.35	0.06	0.33	0.12	0.64	0.19	0.75	0.57	0.02	0.04	0.16
Net Debt	-0.55	-0.97	-0.18	0.34	0.3	-0.66	0.02		0.42	0.32	-0.99	0.33	0.6	-0.99	0.28	-0.1	-0.46	0.32	-0.98	-0.28	0.02	0.26	0.38	0.44	-0.63	0.56
Retained Earnings	-0.73	-0.34	0.41	-0.26	-0.35	-0.5	0.0	0.42		-0.39	-0.35	0.24	0.54	-0.35	0.51	-0.17	-0.95	0.42	-0.34	-0.48	0.4	0.19	0.28	0.97	-0.94	0.88
Accounts Payable	0.02	-0.23	-0.57	0.9	0.98	-0.4	0.52	0.32	-0.39		-0.37	0.54	0.43	-0.37	0.2	0.01	0.3	0.36	-0.26	0.37	-0.14	0.61	0.59	-0.27	0.18	-0.03
Cash	0.54	0.98	0.27	-0.38	-0.34	0.63	0.02	-0.99	-0.35	-0.37		-0.27	-0.54	1.0	-0.24	0.01	0.42	-0.29	0.98	0.29	0.04	-0.23	-0.38	-0.38	0.57	-0.49
Non Current Assets Total	-0.12	-0.14	0.0	0.4	0.53	-0.52	0.92	0.33	0.24	0.54	-0.27		0.84	-0.27	0.45	-0.41	-0.2	0.52	-0.19	0.47	0.38	0.76	0.63	0.25	-0.27	0.45
Non Currrent Assets Other	-0.56	-0.44	0.07	0.46	0.47	-0.78	0.57	0.6	0.54	0.43	-0.54	0.84		-0.54	0.64	-0.36	-0.54	0.69	-0.48	0.08	0.55	0.6	0.59	0.56	-0.63	0.79
Cash And Short Term Investments	0.54	0.98	0.27	-0.38	-0.34	0.63	0.02	-0.99	-0.35	-0.37	1.0	-0.27	-0.54		-0.24	0.01	0.42	-0.29	0.98	0.29	0.04	-0.23	-0.38	-0.38	0.57	-0.49
Non Current Liabilities Total	-0.51	-0.12	0.19	0.29	0.25	-0.9	0.26	0.28	0.51	0.2	-0.24	0.45	0.64	-0.24		0.02	-0.59	0.99	-0.14	-0.39	0.72	0.53	0.63	0.67	-0.65	0.58
Other Current Assets	-0.25	0.08	-0.22	0.06	0.01	0.04	-0.35	-0.1	-0.17	0.01	0.01	-0.41	-0.36	0.01	0.02		0.0	0.02	0.09	-0.38	-0.18	-0.23	0.15	-0.06	0.04	-0.28
Other Stockholder Equity	0.8	0.39	-0.37	0.15	0.25	0.59	0.06	-0.46	-0.95	0.3	0.42	-0.2	-0.54	0.42	-0.59	0.0		-0.51	0.4	0.55	-0.43	-0.2	-0.33	-0.95	0.95	-0.85
Total Liab	-0.48	-0.15	0.09	0.44	0.41	-0.92	0.33	0.32	0.42	0.36	-0.29	0.52	0.69	-0.29	0.99	0.02	-0.51		-0.18	-0.3	0.67	0.61	0.69	0.59	-0.59	0.55
Total Current Assets	0.51	1.0	0.2	-0.3	-0.24	0.54	0.12	-0.98	-0.34	-0.26	0.98	-0.19	-0.48	0.98	-0.14	0.09	0.4	-0.18		0.28	0.05	-0.11	-0.21	-0.34	0.54	-0.46
Common Stock	0.47	0.31	-0.05	0.24	0.35	0.37	0.64	-0.28	-0.48	0.37	0.29	0.47	0.08	0.29	-0.39	-0.38	0.55	-0.3	0.28		-0.07	0.26	-0.11	-0.58	0.59	-0.26
Short Term Debt	-0.35	0.07	0.54	0.02	-0.03	-0.56	0.19	0.02	0.4	-0.14	0.04	0.38	0.55	0.04	0.72	-0.18	-0.43	0.67	0.05	-0.07		0.15	0.09	0.42	-0.43	0.47
Net Receivables	-0.12	-0.07	-0.1	0.54	0.61	-0.56	0.75	0.26	0.19	0.61	-0.23	0.76	0.6	-0.23	0.53	-0.23	-0.2	0.61	-0.11	0.26	0.15		0.74	0.3	-0.26	0.34
Inventory	-0.31	-0.18	-0.34	0.46	0.55	-0.67	0.57	0.38	0.28	0.59	-0.38	0.63	0.59	-0.38	0.63	0.15	-0.33	0.69	-0.21	-0.11	0.09	0.74		0.44	-0.41	0.43
Other Liab	-0.75	-0.33	0.31	-0.14	-0.23	-0.65	0.02	0.44	0.97	-0.27	-0.38	0.25	0.56	-0.38	0.67	-0.06	-0.95	0.59	-0.34	-0.58	0.42	0.3	0.44		-0.96	0.87
Net Tangible Assets	0.84	0.53	-0.27	0.02	0.13	0.72	0.04	-0.63	-0.94	0.18	0.57	-0.27	-0.63	0.57	-0.65	0.04	0.95	-0.59	0.54	0.59	-0.43	-0.26	-0.41	-0.96		-0.89
Other Assets	-0.81	-0.44	0.25	0.13	0.02	-0.66	0.16	0.56	0.88	-0.03	-0.49	0.45	0.79	-0.49	0.58	-0.28	-0.85	0.55	-0.46	-0.26	0.47	0.34	0.43	0.87	-0.89

Click cells to compare fundamentals

GlucoTrack Account Relationship Matchups

GlucoTrack fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	11.9M	15.1M	15.5M	15.5M	4.2M	4.9M
Total Assets	1.3M	10.6M	6.3M	2.4M	4.9M	3.8M
Short Long Term Debt Total	377.6K	363K	250K	195K	196K	246.7K
Other Current Liab	596.1K	392K	229K	341K	673K	594.1K
Total Current Liabilities	2.3M	1.3M	883K	1.0M	1.5M	1.7M
Total Stockholder Equity	(1.4M)	9.0M	5.2M	1.2M	3.2M	3.4M
Property Plant And Equipment Net	321.0K	315K	109K	40K	27K	25.7K
Net Debt	(41.0K)	(9.5M)	(5.8M)	(2.1M)	(4.3M)	(4.1M)
Retained Earnings	(90.7M)	(93.4M)	(97.5M)	(101.9M)	(109.9M)	(104.4M)
Accounts Payable	1.5M	869K	631K	672K	839K	1.0M
Cash	418.6K	9.8M	6.1M	2.3M	4.5M	2.9M
Non Current Assets Total	564.4K	377K	160K	59K	37K	35.2K
Non Currrent Assets Other	186.4K	62K	51K	4K	10K	9.5K
Cash And Short Term Investments	418.6K	9.8M	6.1M	2.3M	4.5M	2.9M
Liabilities And Stockholders Equity	1.3M	10.6M	6.3M	2.4M	4.9M	3.8M
Non Current Liabilities Total	421.8K	279K	227K	195K	196K	186.2K
Other Current Assets	21.4K	56K	43K	67K	376K	394.8K
Other Stockholder Equity	89.0M	102.4M	102.6M	103.1M	113.0M	61.6M
Total Liab	2.7M	1.6M	1.1M	1.2M	1.7M	1.6M
Total Current Assets	718.0K	10.2M	6.1M	2.4M	4.9M	3.4M
Accumulated Other Comprehensive Income	124.1K	15K	(6K)	17K	64K	67.1K
Common Stock	141.6K	162.8K	201K	15K	20K	19K
Net Tangible Assets	(1.4M)	9.0M	5.2M	1.2M	1.4M	1.5M
Other Assets	57K	62K	0.0	19K	1.0	0.95
Property Plant Equipment	321K	315K	109K	40K	36K	34.2K
Long Term Debt	190.4K	197K	210K	195K	196K	212.0K
Net Invested Capital	(1.2M)	9.2M	5.4M	1.4M	3.4M	2.8M
Net Working Capital	(1.6M)	8.9M	5.2M	1.4M	3.4M	2.6M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether GlucoTrack is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlucoTrack Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glucotrack Stock. Highlighted below are key reports to facilitate an investment decision about Glucotrack Stock:

How To Invest In GlucoTrack

Details

Is GlucoTrack Stock a good investment?

Details

What is GlucoTrack's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlucoTrack. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.

You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlucoTrack. If investors know GlucoTrack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlucoTrack listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.91)

Return On Assets

(1.57)

Return On Equity

(5.41)

The market value of GlucoTrack is measured differently than its book value, which is the value of GlucoTrack that is recorded on the company's balance sheet. Investors also form their own opinion of GlucoTrack's value that differs from its market value or its book value, called intrinsic value, which is GlucoTrack's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlucoTrack's market value can be influenced by many factors that don't directly affect GlucoTrack's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between GlucoTrack's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlucoTrack is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlucoTrack's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

GlucoTrack Cost Of Revenue vs Revenue Per Share Analysis

Cost Of Revenue vs Revenue Per Share

Cost Of Revenue vs Revenue Per Share Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Revenue Per Share

GlucoTrack fundamental ratios Correlations

GlucoTrack Account Relationship Matchups

High Positive Relationship

High Negative Relationship

GlucoTrack fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 0.99	Non Current Liabilities Total
Cash	+ 0.98	Total Assets
Cash And Short Term Investments	+ 0.98	Total Assets
Accounts Payable	+ 0.98	Total Current Liabilities

Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Total Current Assets	- 0.98	Net Debt
Net Debt	- 0.97	Total Assets
Net Tangible Assets	- 0.96	Other Liab
Other Liab	- 0.95	Other Stockholder Equity